Business Description
BriaCell Therapeutics Corp
NAICS : 325414
SIC : 3741
ISIN : CA10778Y1043
Share Class Description:
BCTX: Ordinary Shares - NewCompare
Compare
Traded in other countries / regions
BCT.CanadaBCTX.USA8BT.Germany Description
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.41 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10 | |||||
| 3-Year EPS without NRI Growth Rate | -12 | |||||
| 3-Year FCF Growth Rate | 1.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 32.08 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.86 | |||||
| 9-Day RSI | 60.55 | |||||
| 14-Day RSI | 59.94 | |||||
| 3-1 Month Momentum % | 12.19 | |||||
| 6-1 Month Momentum % | -50 | |||||
| 12-1 Month Momentum % | -85.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.49 | |||||
| Quick Ratio | 0.49 | |||||
| Cash Ratio | 0.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -33.11 | |||||
| ROIC % | -1293.33 | |||||
| 3-Year ROIIC % | -1352.34 | |||||
| ROC (Joel Greenblatt) % | -1517.7 | |||||
| ROCE % | -344.78 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.19 | |||||
| EV-to-Forward-EBIT | -1.29 | |||||
| EV-to-EBITDA | -1.2 | |||||
| EV-to-FCF | -1.65 | |||||
| Earnings Yield (Greenblatt) % | -84.03 | |||||
| FCF Yield % | -59.34 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BriaCell Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.17 | ||
| Beta | 1.8 | ||
| 3-Year Sharpe Ratio | -0.48 | ||
| 3-Year Sortino Ratio | -0.68 | ||
| Volatility % | 97.06 | ||
| 14-Day RSI | 59.94 | ||
| 14-Day ATR ($) | 0.129513 | ||
| 20-Day SMA ($) | 0.8264 | ||
| 12-1 Month Momentum % | -85.28 | ||
| 52-Week Range ($) | 0.4641 - 5.97 | ||
| Shares Outstanding (Mil) | 36.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BriaCell Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BriaCell Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BriaCell Therapeutics Corp Frequently Asked Questions
What is BriaCell Therapeutics Corp(BCTX)'s stock price today?
The current price of BCTX is $1.10. The 52 week high of BCTX is $5.97 and 52 week low is $0.46.
When is next earnings date of BriaCell Therapeutics Corp(BCTX)?
The next earnings date of BriaCell Therapeutics Corp(BCTX) is 2024-12-13 Est..
Does BriaCell Therapeutics Corp(BCTX) pay dividends? If so, how much?
BriaCell Therapeutics Corp(BCTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers